HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

Gene Therapy
S HarrowR Rampling

Abstract

Following standard treatment, the prognosis remains poor in patients with high-grade glioma and new therapies are urgently required. Herpes simplex virus 1716 (HSV1716) is an ICP34.5 null mutant that is selectively replication competent and shown to be safe and to replicate following injection into high-grade glioma. We demonstrate that following surgical resection, HSV1716 is safe when injected into the brain adjacent to excised tumour. In all, 12 patients with recurrent or newly diagnosed high-grade glioma underwent maximal resection of the tumour. HSV1716 was injected into eight to 10 sites around the resulting tumour cavity with the intent of infecting residual tumour cells. As clinically indicated, patients proceeded to further radiotherapy or chemotherapy. There has been no clinical evidence of toxicity associated with the administration of HSV1716. Longitudinal follow-up has allowed the assessment of overall survival compared to that of similar patients not treated with HSV1716. Three patients remain alive and clinically stable at 15, 18 and 22 months postsurgery and HSV1716 injection. Remarkably, the first patient in the trial, who had extensive recurrent disease preprocedure, is alive at 22 months since injection of HS...Continue Reading

References

Apr 1, 1992·The Journal of General Virology·A DolanD J McGeoch
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B RajanM Brada
Aug 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S G Arbuck
Aug 10, 2002·Gene Therapy·J HarlandS M Brown

❮ Previous
Next ❯

Citations

Dec 6, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Andreas H JacobsPedro Lowenstein
Feb 9, 2008·Neurosurgical Review·Lee A SelznickJohn Sampson
Sep 1, 2006·Wiener medizinische Wochenschrift·Markus HuttererGuenther Stockhammer
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Kaveh Asadi-Moghaddam, E Antonio Chiocca
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jacqueline Nuss ParkerJames M Markert
May 26, 2009·Chemical Reviews·Christopher Alvarez-BreckenridgeE Antonio Chiocca
Aug 30, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Costas G HadjipanayisNeal A Deluca
Oct 30, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·James M MarkertGeorge Y Gillespie
Nov 20, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yuman FongNancy Kemeny
Jan 1, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Manish K Aghi, E Antonio Chiocca
Apr 5, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark A CurrierTimothy P Cripe
Aug 13, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Timothy P CripePatrick Wk Lee
Apr 16, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gregory K FriedmanG Yancey Gillespie
Sep 3, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·XueQing LunPeter A Forsyth
Oct 17, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hiroaki UchidaJoseph C Glorioso
Feb 23, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Eleonora GambiniPaolo Malatesta
Jan 30, 2007·Nature Clinical Practice. Oncology·Ta-Chiang LiuDavid Kirn
Nov 19, 2005·Nature Reviews. Cancer·Kelley A ParatoJohn C Bell
Oct 19, 2005·Gene Therapy·R ArgnaniR Manservigi
Feb 7, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Peter ForsythMark Hamilton
Nov 22, 2005·Oncogene·Manish Aghi, Robert L Martuza
Nov 22, 2005·Oncogene·J Michael MathisDavid T Curiel
Feb 1, 2012·The Cancer Journal·Ahmed Mohyeldin, Ennio Antonio Chiocca
Feb 1, 2012·The Cancer Journal·Guido WollmannAnthony N van den Pol
Mar 2, 2012·Journal of Virology·James M MarkertRichard J Whitley
Jan 29, 2013·Molekuliarnaia biologiia·N V GubanovaP M Chumakov
Oct 6, 2012·Molecular Cancer Research : MCR·Radhashree MaitraSanjay Goel
Mar 29, 2011·Future Virology·Aziz Alami Chentoufi, Lbachir BenMohamed
Nov 28, 2007·Uirusu·Yukihiro Nishiyama, Fumi Goshima
Jul 7, 2007·Neurosurgical Focus·Deva S JeyaretnaRobert L Martuza
Mar 7, 2008·World Journal of Gastroenterology : WJG·Yan-Xia MiYun-Chun Li
Jul 24, 2014·CNS Oncology·Johanna K Kaufmann, E Antonio Chiocca
Jul 14, 2007·Proceedings of the National Academy of Sciences of the United States of America·Christopher L SkellyBernard Roizman

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.